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Abstract
The study aims to determine the efficacy and feasibility of a novel folate receptor (FR)–based circulating tumor cell
(CTC) detection method in the diagnosis of non–small cell lung cancer (NSCLC). CTCs were collected from 3 ml of
blood based on negative enrichment by immunomagnetic beads and then labeled by a conjugate of a tumor-specific
ligand folate and an oligonucleotide. After washing off redundant conjugates, the bound conjugates were re-
moved and analyzed by quantitative polymerase chain reaction. The captured cells were validated as tumor cells
by immunofluorescence staining. In the evaluation of clinical utility, the results showed that the CTC levels of
153 patients with NSCLC were significantly higher than the controls (49 healthy donors and 64 patients with benign
lung diseases; P < .001). With a threshold of 8.64 CTC units, the method showed a sensitivity of 73.2% and a spec-
ificity of 84.1% in the diagnosis of NSCLC, especially a sensitivity of 67.2% in stage I disease. Compared with the
existing clinical biomarkers such as neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cancer antigen
125 (CA125), cyfra21-1, and squamous cell carcinoma antigen (SCC Ag), the method showed the highest diagnostic
efficiency (area under the curve, 0.823; 95% confidence interval, 0.773-0.874). Together, our results demonstrated
that FR-positive CTCs were feasible diagnostic biomarkers in patients with NSCLC, as well as in early-stage tumors.
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Introduction
Lung cancer is the leading cause of cancer-related death in the world,
and the non–small cell lung cancer (NSCLC) subtype accounts for
about 80% of all cases; the overall 5-year survival rate remains at
approximately 15%, and the majority of patients still present with
advanced disease [1]. Early diagnosis and treatment could improve
the 5-year survival rate by three-fold to four-fold, with the possibility
of cure [2], which need more sensitive and specific methods. Low-dose
computed tomography is an effective mean for early diagnosis and
screening, which could reduce the mortality of lung cancer by 20%
[3]. However, a high rate of false positives to small nodules and central
tumors still represents a distinct clinical entity [4].
Circulating tumor cells (CTCs) have recently emerged as impor-
tant potential biomarkers of diagnosis, evaluation of treatment effect,
and prognosis in several epithelial cancers including lung cancer. Be-
cause of epithelial-to-mesenchymal transition, the recent methods
of epithelial cell adhesion molecule (EpCAM)-based CTC analysis
showed limitations to detect CTCs in patients with malignant
tumors [5]. CTCs in patients with NSCLC often present with none-
pithelial characteristics [6]. A prospective study demonstrated that
only 32% of patients (19/60) with distant metastatic NSCLC had
positive CTC counts at baseline by using CellSearch System [7].
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The folate receptors (FRs) are highly expressed in a variety of can-
cers, especially in ovarian and lung cancers, whereas most normal
tissues express low to negligible levels [8]. Therefore, FR may be a
potential target for capturing CTCs in patients with NSCLC. A
novel FR-based CTC analysis method had been developed on the basis
of this fact. This study aims to determine the efficacy and feasibility
of the FR-based CTC detection method in the diagnosis of NSCLC,
especially for early-stage tumors.
Materials and Methods
Patients and Control Sample Selection
The current prospective study was approved by the Institutional
Review Board at Cancer Hospital, Peking Union Medical College
and Chinese Academy of Medical Sciences (Approval No. 13-031/
707), and informed written consent was obtained from all subjects
before the study. This study was registered with the Chinese Clinical
Trial Registry (ChiCTR-DDT-13003251). One hundred fifty-three
consecutive patients with lung adenocarcinoma (ADC) or squamous
cell carcinoma (SCC) undergoing treatment were enrolled into the
study, from May 2013 to July 2013. All patients were established on
the diagnosis by cytologic or pathologic examinations. None of the
patients had received any anticancer therapies or with a history of other
cancers before this study. Disease stages were based on the seventh
edition of the American Joint Committee on Cancer staging manual.
In addition, peripheral blood samples were obtained from 49 healthy
donors who exhibited no evidence of any clinically detectable disease
after health checkups and 64 patients who were diagnosed with benign
lung disease based on imaging or pathologic examinations. Patient data
are presented in Table 1.
Processing of Blood Samples
To prevent the contamination of epithelial cells, a catheter was used
and the first 5 ml of blood was discarded. Following this, peripheral
blood samples were collected in the 6-ml EDTA-containing tubes
(BD Diagnostics, Sparks, MD). Samples were stored at 4°C and
processed within 24 hours of blood withdrawal. Blood samples were
taken from an antecubital vein in all patients who were scheduled for
surgery. Technologists who operated the detection of CTCs were
blinded to the sample groups. All samples had been de-identified
before technologists received them.
Detection of CTCs
The CytoploRare Circulating Lung Cancer Cell Kit was provided by
GenoSaber Biotech Co Ltd (Shanghai, China). The fundamental prin-
ciples of this kit was designed as previously described [9,10] and had
been modified for detection of CTCs in patients with lung cancer.
In short, the method comprises two components: one is for CTC
enrichment that is based on negative enrichment by immunomagnetic
beads, and the other is for CTC detection and quantification that is
based on ligand-targeted polymerase chain reaction (PCR). The primer
sequences were listed as follows: reverse transcription (RT) primer
(a oligonucleotide that is conjugated to the tumor-specific ligand folic
acid), 5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTT-
GAGGGTTCTAA-3′; forward primer, 5′-TATGATTATGAGGCA-
TGA-3′; reverse primer, 5′-GGTGTCGTGGAGTCG-3′; TaqMan
probe, 5′-FAM-CAGTTGAGGGTTC-MGB-3′.
Following the manufacturer’s instruction manual, 3 ml of whole
blood samples was lysed of erythrocytes with red cell lysis buffer
(vol/vol, 1:4) for 15 minutes at 4°C and then depleted of leukocytes
with 150 μl of anti-CD45 magnetic beads and macrophages with
50 μl of anti-CD14 beads for 30 minutes at 4°C. Following that,
enriched CTCs were incubated with 10 μl of labeling buffer that
contained conjugates of a tumor-specific ligand folic acid and a syn-
thesized oligonucleotide for 40 minutes at room temperature. The
samples were then washed three times with 1 ml of wash buffer and,
then at 500 rpm for 10 minutes at 4°C to remove the unbound con-
jugates. The specific ligand–oligonucleotide conjugates were removed
with 120 μl of stripping buffer for 2 minutes at 4°C, collected by
centrifugation, and neutralized by 24 μl of neutralization buffer for
further RT-PCR analysis.
In the phase of PCR analysis, RT-PCR and data collection were
performed with an ABI 7300 StepOne System (Life Technologies,
Carlsbad, CA). The following reaction conditions were used on the
ABI 7300 instrument: denaturation at 95°C for 2 minutes, annealing
at 40°C for 30 seconds, extension at 72°C for 30 seconds, and then
cooling at 8°C for 5 minutes; 40 cycles of denaturation at 95°C
for 10 seconds, annealing at 35°C for 30 seconds, and extension at
72°C for 10 seconds.
A self-defined measurement, named CTC unit, which was defined
as the number of CTCs detected in 3 ml of blood, was used in our
study. If one CTC was detected in 3 ml of blood, it was defined
as one CTC unit. A series of standards containing oligonucleotides
Table 1. Patient Characteristics.
Characteristics No.
NSCLC (n = 153)
Age, years (mean, range) 59.4 years (25-85 years)
Sex (male/female) 99/54
Smoking 88 (57.5%)
MTD (mean, range) 3.4 cm (0.8-11 cm)
T stage
T1 43 (28.1%)
T2 89 (58.2%)
T3 13 (8.5%)
T4 8 (5.2%)
N stage
N0 82 (53.6%)
N1 34 (22.2%)
N2 34 (22.2%)
N3 3 (2%)
M stage
M0 145 (94.8%)
M1 8 (5.2%)
Grade
Well differentiated (G1) 16 (10.5%)
Moderately differentiated (G2) 88 (57.5%)
Poorly differentiated (G3) 49 (32%)
TNM stage
I 67 (43.8%)
II 36 (23.5%)
III 42 (27.5%)
IV 8 (5.2%)
Histopathologic subtype
ADC 102 (66.7%)
SCC 51 (33.3%)
Healthy donors (n = 49)
Age, years (mean, range) 38.3 years (23-75 years)
Sex (male/female) 26/23
Smoking 10 (20.4%)
Benign diseases (n = 64)
Age, years (mean, range) 51 years (23-77 years)
Sex (male/female) 32/32
Smoking 29 (45.3%)
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(from 10−14 to 10−9 M, corresponding to from 2 to 2 × 105 CTC units)
is used for CTC quantification. All blood samples were tested in
duplicates with six standards and three quality controls (Figure 1A).
Immunofluorescence Staining of Enriched CTCs
The enriched CTCs from 3 ml of blood sample were fixed by
methanol for 10 minutes at −20°C. Then, these cells were washed
with phosphate-buffered saline for 1 minute and stained with
phycoerythrin-conjugated pan-cytokeratin monoclonal antibody
(sc-8018PE; Santa Cruz Biotechnology, Dallas, TX) and Alexa Fluor
488–conjugated folic acid that was synthesized by WuXi AppTec Co
(Shanghai, China), on the basis of the previously reported literature
[9], for 1 hour at room temperature. After washing with phosphate-
buffered saline, samples were finally mounted with 4′-6-diamidino-2-
phenylindole–containingmountingmedia (D3571; Life Technologies).
Imaging was carried out with an inverted Nikon ECLIPSE TE2000-S
microscope (Nikon, Tokyo, Japan).
Statistical Analysis
The CTC units were presented as median and interquartile range.
We compared the CTC unit between two groups using the Mann-
Whitney U test and among three groups or more using the Kruskal-
Wallis test. The most efficient cutoff values to discriminate patients
with cancer from non-cancer controls were identified using receiver
operating characteristic (ROC) curve analysis, and the area under the
ROC curve (AUC) was calculated for each index. The Youden index
was used to identify the optimal cutoff point and diagnostic efficiency.
All P values were based on two-sided testing, and statistical analyses
were performed with SPSS 18.0 software (SPSS Inc, Chicago, IL) or
the Prism 5.0 (GraphPad Software Inc, San Diego, CA).
Results
Patient Characteristics
CTC levels in clinical samples. To evaluate the specificity of FR
expression on CTCs, immunofluorescence staining was performed at
first. As shown in Figure 1, B to E , the heterocyst is labeled by red
(phycoerythrin-conjugated anti–pan-cytokeratin) and green (Alexa
Fluor 488–folate), with a giant and multishaped nucleus (4′-6-
diamidino-2-phenylindole). In contrast, the leukocytes cannot be
Figure 1. (A) The flowchart of CytoploRare Circulating Lung Cancer Cell Kit: I, lysis of erythrocytes; II, treatment with anti-CD45 and anti-
CD14 magnetic beads; III, immunomagnetic depletion of leukocytes and macrophages; IV, incubation with conjugates of a tumor-specific
ligand folic acid and a synthesized oligonucleotide; V, removal of the unbound conjugates; VI, dissection of oligonucleotides from spe-
cific bound conjugates and collection; VII, addition of the prepared samples into the PCR System; VIII, PCR amplification; IX, data analysis.
(B–E) Confocal microscopic analysis of an isolated CTC from a patient with NSCLC. Cytokeratin (B), folate (C), and nucleus (D) images are
merged on E. In contrast, the leukocytes cannot be stained by red and green fluorescein (B–C) and with only small nuclei (D–E).
Figure 2. (A) The CTC levels of healthy donors, patients with benign lung diseases, and patients with NSCLC. (B) The CTC levels of
healthy donors, patients with benign lung diseases, and patients with stage I NSCLC.
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stained by red and green fluorescein (Figure 1, B and C ) and only with
small nuclei (Figure 1, E and F).
The median CTC units were 5.71 [4.03-7.38], 6.74 [4.64-8.27],
and 10.82 [8.21-15.84] in healthy donors, benign diseases, and
patients with NSCLC, respectively. Compared with patients with
NSCLC, the CTC levels were significantly lower in healthy donors
and benign diseases (P < .001). However, there was no significant
difference between the two control groups (P = .105; Figure 2A).
To further evaluate the efficacy and feasibility of FR-based CTC
detection method in early diagnosis, we analyzed the diagnostic
values of the CTC unit in patients with stage I NSCLC. The me-
dian CTC units were 5.71 [4.03-7.38], 6.74 [4.64-8.27], and 9.95
[6.8-14.88] in healthy donors, benign diseases, and patients with stage
I NSCLC, respectively. Compared with control groups, the CTC levels
were significantly higher in patients with stage I NSCLC (P < .001;
Figure 2B).
To investigate the significance of CTC levels in patients with
NSCLC, the clinical and pathologic characteristics of individuals,
including age at diagnosis (≤60 years vs >60 years), sex (male vs
female), history of smoking, maximum tumor diameter (MTD, ≤3 cm
vs >3 cm), grade of tumor (G1 vs G2 vs G3), TNM stage (I-II vs
III-IV), and histopathologic subtypes (ADC vs SCC) were also tested
for association with CTC levels, and the results are shown in Table 2.
The CTC levels of patients with bigger tumor or advanced stage dis-
eases or SCC were higher than those with smaller tumor or early-stage
diseases or ADC (all at P < .05; Figure 3, A–C).
ROC analysis. ROC curves were plotted to determine the diag-
nostic efficiency of CTC levels for NSCLC (ADC and SCC), and
the Youden index was used to identify the cutoff point, which meant
to choose the “optimal” threshold value when the threshold value for
sensitivity + specificity − 1 was maximized. Figure 1 shows that the
cutoff value between control groups and NSCLC group is 8.64 CTC
units, with the sensitivity of 73.2%, the specificity of 84.1%, and the
AUC of 0.823 [95% confidence interval (CI), 0.773-0.874].
With the cutoff point of 8.64 CTC units, the sensitivity was
67.2% (45/67) in the diagnosis of patients with stage I NSCLC
by using the FR-based CTC detection method. In patients with stage
II, III, and IV NSCLC, the sensitivities were 69.4% (25/36), 80.9%
(34/42), and 100% (8/8), respectively. In patients with different histo-
pathologic subtypes, the sensitivities for ADC was 70.6% (72/102),
Table 2. The CTC Levels in Patients with NSCLC.
Characteristics CTC Unit, Median (Interquartile Range) P Value
Age
≤60 years 11.29 [8.35-15.85] .551
>60 years 10.24 [8.14-15.62]
Sex (male/female)
Male 10.7 [7.65-15.91] .78
Female 10.87 [8.99-15.22]
Smoking
Yes 10.83 [7.72-16.41] .975
No 10.82 [8.96-15.17]
MTD
≤3 cm 9.92 [6.8-14.1] .001
>3 cm 12.49 [9.78-18.06]
Grade
G1 10.31 [8.79-18.78] .94
G2 10.57 [7.76-15.8]
G3 11.43 [8.16-15.84]
TNM stage
I and II 9.95 [7.23-15.2] .007
III and IV 12.4 [10-19.56]
Histopathologic subtype
ADC 10.28 [7.49-15.15] .038
SCC 12.21 [9.46-17.28]
Figure 3. (A) The CTC levels between patients with stage I and II NSCLC and those with stage III and IV NSCLC. (B) The CTC levels
between patients with MTD ≤ 3 cm and those with MTD > 3 cm. (C) The CTC levels between patients with ADC and those with SCC.
(D) ROC curve analyses of the use of CTC, neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125),
cyfra21-1, and squamous cell carcinoma antigen (SCC Ag) to differentiate patients with NSCLC and controls. (E) The sensitivity of different
markers in all NSCLCs and stage I NSCLCs. (F) The specificity of different markers in controls.
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and for SCC, it was 78.4% (40/51), respectively. The sensitivities
for ADC and SCC at stage I were 66.7% (36/54) and 69.2%
(9/13), respectively.
Comparison of the existing clinical biomarkers. To further
analyze the diagnostic efficiency of the FR-based CTC detection
method in patients with NSCLC, we compared it with the existing
clinical biomarkers (NSE, CEA, CA125, cyfra21-1, and SCC Ag).
These tumor markers were analyzed with an Elecsys immunoassay
analyzer (Roche Diagnostics, Bavaria, Germany).
As shown in Figure 3, D to F , and Table 3, the FR-based CTC
detection method displays the highest AUC (0.823; 95% CI,
0.773-0.874) and Youden index (0.573) compared with these five
biomarkers and could satisfactorily discriminate patients with NSCLC
from controls, even in early-stage NSCLC.
Discussion
Sensitive and specific detection and enumeration of CTCs remain a
challenge in patients with NSCLC; however, it is still a developing
field, with no universal method of detection suitable for all types of
cancer [6]. The CellSearch System (Veridex, Raritan, NJ) is the pioneer
in developing a standardized commercial system for CTC detection,
which has gained approval from the US Food and Drug Administration
for providing CTC enumeration tests in advanced breast, prostate,
and colon cancers [11]. However, this technique relies on the use of
epithelial markers to identify CTCs, loss of these markers during
epithelial-to-mesenchymal transition in lung cancer can render these
methods ineffective [6,12]. In addition, it is difficult to detect CTCs
in NSCLC using EpCAM-based CTC chip devices for similar reasons.
Isolation by size of epithelial tumor cells is another CTC detection
technology based on morphologic features without involving immuno-
labeling of cell surface markers. Previous studies found that more
CTCs and higher positive rate were identified by the isolation by
size of epithelial tumor cells method compared with CellSearch in
patients with lung cancer [13]. However, lack of subsequent classic
cytopathologic assessment of the captured cells and the possibility of
false-positive diagnosis stress the need for using immunophenotypic
characterization methods to improve this approach [14].
The FR, a cell-surface receptor glycoprotein, which is over-
expressed mainly in ovarian and lung cancer tumors, has become
an important potential drug target for patients with NSCLC [15].
A study found that FR expression was upregulated in about 75.7%
of patients with NSCLC and that higher levels of FR expression
were seen in ADC than SCC [16]. Although some normal tissues
including normal lung tissues can also express FRs, there are no normal
cells in blood except a subgroup of activated macrophages that could
express functional FRs [9]. However, these activated macrophages
are barely detectable in the blood samples from healthy donors or
benign diseases [10]. In the present study, we used the FR-based
CTC detection method in patients with NSCLC, and lower CTC
levels were found in the control groups compared with NSCLC
groups (P < .001).
Ligand-targeted PCR is another important technology in our CTC
detection method, which is based on negative selection of CTCs,
followed by labeling with folate-linked oligonucleotide and sub-
sequent quantification with RT-PCR. Parker et al. identified that
NSCLC samples expressed an average level of FR at 6.11 pmol
FR/mg solubilized membrane protein by using a quantitative radio-
ligand binding assay, which meant that there were about more than
100,000 FRs in the surface of one NSCLC cell [8]. One CTC in
the peripheral blood of patients with NSCLC was increased by almost
100,000 order of magnitude after the binding of folate-linked oligonu-
cleotide and FR, and these oligonucleotides could be further amplified
by using RT-PCR. On the basis of the two-step method of enlarge-
ment, a small amount of CTCs could be detected in as low as 3 ml
of blood samples. Our results showed that the sensitivity was 73.2%
and the specificity was 84.1% by using the FR-based CTC detection
method for the entire cohort (Table 3).
Previously, oncologists thought that the development of cancer
was a stepwise progression accompanied by accumulation of genetic
and epigenetic alterations. During local progression, aggressive cells
were selected and dissemination initiates; the cells became increasingly
malignant until they form metastases in distant organs and killed the
patient. Long ago, shedding of the tumor cells into the blood was con-
sidered as a terminal event according to the linear progression model,
but this theory had difficulty in explaining the distant metastases that
occur in some early-stage cancers or even before diagnosis of primary
tumors [17]. The parallel progression model believed that CTCs were
released at an early stage of cancer progression, and the primary tumor
and metastasis grew in parallel, long before the first symptoms of
cancer appear [18]. A recent study confirmed that CTCs could be
detected in very early stage during tumor development, even at a
premalignant stage in a pancreatic cancer model [19], which implied
that CTCs could be potential biomarkers for early diagnosis of cancer.
Our results also showed that the sensitivity was 67.2% in diagnosing
patients with stage I NSCLC by using the FR-based CTC detection
method. The sensitivities were 66.7% and 69.2% in patients with
stage I ADC and SCC, respectively.
Subjects in our study also accepted detection of the existing
lung tumor biomarkers, such as NSE, CEA, CA125, cyfra21-1,
and SCC Ag, and we compared diagnostic efficacies of FR-based
CTC detection with these five biomarkers. FR-based CTC detection
method showed the highest AUC and Youden index compared with
other biomarkers (Table 3). In the diagnosis of early-stage NSCLC,
five clinical biomarkers showed a significantly reduced diagnostic
efficacy except cyfra21-1, but FR-based CTCs still maintained a satis-
factory diagnostic sensitivity. Compared with five clinical biomarkers,
the specificity of FR-based CTCs was lowest but acceptable.
Table 3. The Diagnostic Efficiency of the FR-Based CTC, NSE, CEA, CA125, Cyfra21-1, and SCC Ag in Patients with NSCLC and Early-Stage NSCLC.
Diagnostic Method Cutoff Point Sensitivity (%) Specificity (%) Youden Index Sensitivity of Stage I NSCLC (%) AUC (95% CI)
CTC 8.64 CTC units 73.2 84.1 0.573 67.2 0.823 (0.773-0.874)
NSE 18 ng/ml 9.6 95.9 0.055 4.6 0.585 (0.495-0.675)
CEA 5 ng/ml 30.1 94.9 0.25 18.5 0.76 (0.69-0.83)
CA125 35 U/ml 19.9 97.6 0.175 4.6 0.505 (0.417-0.592)
Cyfra21-1 3.3 ng/ml 45.2 90 0.352 32.3 0.716 (0.615-0.816)
SCC Ag 1.5 ng/ml 21.2 93.8 0.15 12.3 0.624 (0.535-0.713)
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Studies on CTC detection in NSCLC had identified a correlation
between disease stages and number of CTCs [7], and our results also
found that the number of CTCs was higher in patients with stage
III/IV NSCLC compared with patients with stage I/II disease. We
also investigated the correlation between CTC levels and primary
tumor load. Significantly lower CTC levels were found in patients
with maximum diameter of primary tumor ≤3 cm compared with
those >3 cm, which meant that the quantification of CTCs might
be a good surrogate of tumor load. However, previous studies re-
ported that FR expression was much lower in SCC than in ADC
[8], and our results found that the CTC levels of SCC were higher
than those of ADC (Figure 3C ; P = .038). A probable explanation to
the contradictory finding is that gene expression between primary
tumors and CTC samples is different [20], which leads to the dif-
ferent expression level of FR between them. However, the hypothesis
needs to be verified in the further study.
In conclusion, our results suggested that FR-positive CTCs
were feasible diagnostic biomarkers in NSCLC, even in early-stage
tumors. Further investigation on the correlation between the pre-
operative CTC levels and the prognosis of patients with NSCLC
is required.
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